Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study.

ABSTRACT:

Background

High budget impact (BI) estimates of new drugs limit access to patients due to concerns regarding affordability and displacement effects. The accuracy and methodological quality of BI analyses are often low, potentially mis-informing reimbursement decision making. Using hepatitis C as a case study, we aim to quantify the accuracy of the BI predictions used in Dutch reimbursement decision-making and to characterize the influence of market-dynamics on actual BI.

Methods

We selected hepatitis C direct-acting antivirals (DAAs) that were introduced in the Netherlands between January 2014 and March 2018. Dutch National Health Care Institute (ZIN) BI estimates were derived from the reimbursement dossiers. Actual Dutch BI data were provided by FarmInform. BI prediction ac

SUBMITTER: Geenen JW 

PROVIDER: S-EPMC6652171 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature